Your browser doesn't support javascript.
loading
The Use of Osteobiologics in Single versus Multi-Level Anterior Cervical Discectomy and Fusion: A Systematic Review.
Hoffmann, Jim; Ricciardi, Guillermo A; Yurac, Ratko; Meisel, Hans Jörg; Buser, Zorica; Qian, Bangping; Vergroesen, Pieter-Paul A.
Afiliación
  • Hoffmann J; Department of Orthopaedics, Alrijne Hospital, Leiderdorp, The Netherlands.
  • Ricciardi GA; Spine Surgery, Orthopaedics and Traumatology, Centro Mdico Integral Fitz Roy, Buenos Aires, Argentina.
  • Yurac R; Spine Surgery, Orthopaedics and Traumatology, Sanatorio Gemes, Buenos Aires, Argentina.
  • Meisel HJ; Professor associate of Orthopedics and Traumatology, University of Development, Santiago, Chile.
  • Buser Z; Spine Unit, Department of Orthopedics and Traumatology, Clinica Alemana, Santiago, Chile.
  • Qian B; Department of Neurosurgery, BG Klinikum Bergmannstrost, Halle, Germany.
  • Vergroesen PA; Department of Orthopedic Surgery, NYU Grossman School of Medicine, New York, USA.
Global Spine J ; 14(2_suppl): 110S-119S, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38421334
ABSTRACT
STUDY

DESIGN:

Systematic literature review.

OBJECTIVES:

In this study we assessed evidence for the use of osteobiologics in single vs multi-level anterior cervical discectomy and fusion (ACDF) in patients with cervical spine degeneration. The primary objective was to compare fusion rates after single and multi-level surgery with different osteobiologics. Secondary objectives were to compare differences in patient reported outcome measures (PROMs) and complications.

METHODS:

After a global team of reviewers was selected, a systematic review using different repositories was performed, confirming to PRISMA and GRADE guidelines. In total 1206 articles were identified and after applying inclusion and exclusion criteria, 11 articles were eligible for analysis. Extracted data included fusion rates, definition of fusion, patient reported outcome measures, types of osteobiologics used, complications, adverse events and revisions.

RESULTS:

Fusion rates ranged from 87.7% to 100% for bone morphogenetic protein 2 (BMP-2) and 88.6% to 94.7% for demineralized bone matrix, while fusion rates reported for other osteobiologics were lower. All included studies showed PROMs improved significantly for each osteobiologic. However, no differences were reported when comparing osteobiologics, or when comparing single vs multi-level surgery specifically.

CONCLUSION:

The highest fusion rates after 2-level ACDF for cervical spine degeneration were reported when BMP-2 was used. However, PROMs did not differ between the different osteobiologics. Further blinded randomized trials should be performed to compare the use of BMP-2 in single vs multi-level ACDF specifically.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Global Spine J Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Global Spine J Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos